|

AUCD Community Inclusion

AUCD’s Community Inclusion Team supports the University Centers for Excellence in Developmental Disabilities (UCEDD) Network in partnership with the Administration for Community Living.

Learn More
|

AUCD Maternal and Child Health Engagement

AUCD’s Maternal and Child Health Engagement supports the Autism CARES Programs, including LEND and DBP Programs.

Learn More
|

AUCD Public Health

AUCD’s Public Health Team works to create health promotion and public health efforts that include people with disabilities.

Learn More
|

AUCD Emerging Leaders Community

AUCD Emerging Leaders are a part of a community that includes trainees, early career professionals, self-advocates, and family members from AUCD member Centers and Programs.

Learn More

Donate

Product

Journal: An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.

Center:

CA-UC Davis at the MIND Institute, UCEDD/LEND

Fiscal Year:

2024

Contact Information:

Randi Hagerman
[email protected]
916-703-0247

Product Description:

Behavioral interventions remain the mainstay of treatment of autism spectrum disorder (ASD). However, several potential targeted treatments addressing the underlying neurophysiology of ASD have emerged in the last few years. Commonly used medications to address the comorbidities associated with ASD are reviewed. Targeted treatments in Fragile X syndrome (FXS), the most common genetic disorder leading to ASD, provide a model for new treatments that may be helpful for other forms of ASD.

Keyword(s):

Autism, Psychopharmacological Treatment

Product/Publication Type(s):

Peer-reviewed publications in scholarly journals Published/In Press

Target Audience:

Professionals

Alternative Format:

To Obtain Copies (URL or Email):

https://doi.org/10.1176/appi.focus.24022006

COVID-19 Related Data:

N/A

1100 Wayne Avenue, Suite 1000 Silver Spring, MD 20910